Rassnick K M, Moore A S, Collister K E, Northrup N C, Kristal O, Chretin J D, Bailey D B
Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, PO Box 31, Ithaca, NY 14853, USA.
J Vet Intern Med. 2009 Mar-Apr;23(2):317-22. doi: 10.1111/j.1939-1676.2008.0270.x. Epub 2009 Feb 2.
Chemotherapy for multicentric canine lymphoma has favorable results. The gastrointestinal (GI) tract is the most common extranodal site of canine lymphoma, but there have been no prospective studies to determine outcome when dogs with GI lymphoma are treated with chemotherapy.
Treatment with a multiagent chemotherapy protocol is associated with a poor outcome in dogs with GI lymphoma.
Eighteen dogs with histologically confirmed GI lymphoma.
Prospective clinical trial in which dogs with GI lymphoma were treated with a 20-week combination chemotherapy protocol consisting of induction and consolidation phases.
Thirteen dogs had primary GI lymphoma and 5 had multicentric lymphoma with GI involvement. The majority of the lymphomas (63%) were of T-cell origin. Overall remission rate was 56%; 9 dogs achieved a complete remission for a median of 86 days (range, 22-420 days) and 1 dog achieved a partial remission for 26 days. Overall median survival time was 77 days (range, 6-700 days). Dogs that failed to achieve a remission (10 versus 117 days; P= .002) or had diarrhea at initial presentation (70 versus 700 days; P < .001) had shorter survival times.
The response and survival of dogs with GI lymphoma treated with multiagent chemotherapy is poor but long-term survival is possible.
多中心型犬淋巴瘤的化疗效果良好。胃肠道是犬淋巴瘤最常见的结外部位，但尚无前瞻性研究来确定胃肠道淋巴瘤犬接受化疗后的预后情况。
采用多药联合化疗方案治疗的胃肠道淋巴瘤犬预后不良。
18只经组织学确诊为胃肠道淋巴瘤的犬。
前瞻性临床试验，对胃肠道淋巴瘤犬采用为期20周的联合化疗方案，包括诱导期和巩固期。
13只犬为原发性胃肠道淋巴瘤，5只为多中心型淋巴瘤伴胃肠道受累。大多数淋巴瘤（63%）为T细胞起源。总体缓解率为56%；9只犬达到完全缓解，中位缓解期为86天（范围22 - 420天），1只犬达到部分缓解26天。总体中位生存时间为77天（范围6 - 700天）。未达到缓解的犬（10天对117天；P = 0.002）或初次就诊时有腹泻的犬（70天对700天；P < 0.001）生存时间较短。
多药联合化疗治疗的胃肠道淋巴瘤犬的缓解情况和生存情况较差，但长期生存是有可能的。
